


Supplementary materials



Supplementary Figure 1. Asthma symptoms, activity limitations, and rescue medication use (intent-to-treat population [ITT] population). Data presented as mean \pm SD, unless specified otherwise. Except where otherwise stated, data relate to the week immediately prior to each of the stated timepoints

Supplementary Table 1. Asthma-related healthcare resource utilization at months 12 and 24

Factor	Baseline	Month 12	Month 24
Asthma-related hospitalizations	0.8 \pm 1.20 <i>n</i> = 201	0.0 \pm 0.18 <i>n</i> = 182	0.0 \pm 0.16 <i>n</i> = 163
Days stayed in hospital due to asthma	7.9 \pm 11.98 <i>n</i> = 194	0.2 \pm 1.71 <i>n</i> = 182	0.2 \pm 1.61 <i>n</i> = 163
Asthma-related emergency room visits	2.0 \pm 2.80 <i>n</i> = 197	0.0 \pm 0.22 <i>n</i> = 182	0.0 \pm 0.19 <i>n</i> = 163
Unscheduled asthma-related doctor visits (for urgent asthma treatment)	4.9 \pm 3.43 <i>n</i> = 201	0.2 \pm 0.63 <i>n</i> = 182	0.2 \pm 0.67 <i>n</i> = 163
Asthma-related medical healthcare uses*	7.7 \pm 5.96 <i>n</i> = 197	0.3 \pm 0.83 <i>n</i> = 182	0.3 \pm 0.82 <i>n</i> = 163
Missed workdays due to asthma	16.8 \pm 15.18 <i>n</i> = 77	1.2 \pm 8.09 <i>n</i> = 90	0.3 \pm 1.15 <i>n</i> = 82
Missed school days due to asthma	9.3 \pm 12.10 <i>n</i> = 10	0.0 <i>n</i> = 15	0.0 <i>n</i> = 14

Data are presented as mean \pm SD.

*Total number of asthma-related medical health care uses was only calculated if all 3 parameters are given (asthma-related hospitalizations, emergency room visits, and unscheduled doctor visits).

Supplementary Table 2. Oral corticosteroid use in patients at months 12 and 24

	Baseline	Month 12	Month 24
Number of patients using OCS as maintenance therapy, <i>n</i> (%)	70 (34.7)	31 (17.0)	25 (15.3)
Total daily dose (in prednisolone equivalent) [mg]	16.9 \pm 10.81	7.7 \pm 11.56	5.5 \pm 7.30
Change in total daily dose (in prednisolone equivalent) [mg]	–	–9.1 \pm 9.69	–11.0 \pm 12.31
Reduction in total daily dose from BL (%)	–	–57.4 \pm 46.50	–62.0 \pm 45.87
Patients who either reduced or stopped OCS therapy, <i>n</i> (%)	–	39 (63.9)	38 (70.4)
Time to reduction or discontinuation of OCS therapy (days)	–	206.7 \pm 131.48	255.1 \pm 203.00

Values are presented as mean \pm SD, unless specified otherwise.

OCS – oral corticosteroids.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>)